Filtered By:
Specialty: Hematology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 1625 results found since Jan 2013.

Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project.
CONCLUSION:  In AF patients, the ABC-stroke and ABC-bleeding scores demonstrated similar predictive ability for outcomes beyond stroke and bleeding, including MI, acute HF, a composite of cardiovascular events, and all-cause deaths. This is consistent with nonspecificity of biomarkers that predict "sick" patients or poor prognosis overall. PMID: 32506417 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 6, 2020 Category: Hematology Authors: Camelo-Castillo A, Rivera-Caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V Tags: Thromb Haemost Source Type: research

Comparison of risk of serious cardiovascular events after haemorrhagic versus ischaemic stroke: a population-based study
CONCLUSIONS: The risk of subsequent cardiovascular events is similar between patients with incident haemorrhagic or ischaemic stroke. Patients with previous haemorrhagic stroke should be regarded as a population at very-high risk of subsequent CVD.PMID:35688459 | DOI:10.1055/a-1873-9092
Source: Thrombosis and Haemostasis - June 10, 2022 Category: Hematology Authors: Ralph Kwame Akyea Georgios Georgiopoulos Barbara Iyen Joe Kai Nadeem Qureshi George Ntaios Source Type: research

Severe stroke: patient profile and predictors of favorable outcome
Conclusions:  Severe stroke presentation is predicted by multiple clinical, radiologic and metabolic variables, several of which are modifiable. Predictors in the 28% of patients with favorable outcome despite presenting with severe stroke include hypolipemic pretreatment, lower acute temperature, lower glucose levels at 24 h, and arterial recanalization.
Source: Journal of Thrombosis and Haemostasis - January 27, 2013 Category: Hematology Authors: O. BILL, P. ZUFFEREY, M. FAOUZI, P. MICHEL Tags: ORIGINAL ARTICLE Source Type: research

D-dimer and the Risk of Stroke and Coronary Heart Disease. The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.
Abstract D-dimer, a biomarker of coagulation, is higher in blacks than in whites and has been associated with stroke and coronary heart disease (CHD). It was our objective to assess the association of higher D-dimer with stroke and CHD in blacks and whites. REGARDS recruited 30,239 black and white participants across the contiguous US and measured baseline D-dimer in stroke (n=646) and CHD (n=654) cases and a cohort random sample (n=1,104). Cox models adjusting for cardiovascular risk factors determined the hazard ratio (HR) for increasing D-dimer for cardiovascular disease with bootstrapping to assess the differe...
Source: Thrombosis and Haemostasis - December 21, 2016 Category: Hematology Authors: Zakai NA, McClure LA, Judd SE, Kissela B, Howard G, Safford M, Cushman M Tags: Thromb Haemost Source Type: research

Stroke etiologic subtype may influence the rate of hyperdense middle cerebral artery sign disappearance after intravenous thrombolysis
This study suggests that stroke due to LAA is associated with lower rates of HMCAS disappearance, neurologic improvement, and mRS ≤1 after IV thrombolysis, compared with cardioembolic stroke.
Source: Journal of Thrombosis and Thrombolysis - December 31, 2016 Category: Hematology Source Type: research

Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence.
Abstract Despite great efforts in stroke research, disability and recurrence rates in ischaemic stroke remain unacceptably high. To address this issue, one potential target for novel therapeutics is the glycoprotein von Willebrand factor (vWF), which increases in thrombogenicity especially under high shear rates as it bridges between vascular sub-endothelial collagen and platelets. The rationale for vWF as a potential target in stroke comes from four bodies of evidence. (1) Animal models which recapitulate the pathogenesis of stroke and validate the concept of targeting vWF for stroke prevention and the use of the...
Source: Thrombosis and Haemostasis - May 31, 2018 Category: Hematology Authors: Buchtele N, Schwameis M, Gilbert JC, Schörgenhofer C, Jilma B Tags: Thromb Haemost Source Type: research

Increased platelet procoagulant potential predicts recurrent stroke and TIA after lacunar infarction.
CONCLUSIONS: Identification of increased platelet procoagulant potential may improve our ability to identify patients at higher risk of recurrent stroke/TIA following a lacunar stroke. Further study of mechanisms involved is warranted and may yield novel targets for prevention and treatment. PMID: 31858724 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 18, 2019 Category: Hematology Authors: Kirkpatrick AC, Vincent AS, Dale GL, Prodan CI Tags: J Thromb Haemost Source Type: research

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Abstract Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported. In the absence of head to head trials directly comparing these NOACs against each other, we compared the efficacy and safety of edoxaban to other agents by an indirect comparison analysis. We performed an indirect comparison analysis of edoxaban (2 dose strategies) against apixaban (1 dose), dabigatran etexilate (2 doses) and rivaroxaban (1 dose), for their relative efficacy and safety against ea...
Source: Thrombosis and Haemostasis - February 28, 2014 Category: Hematology Authors: Skjøth F, Larsen TB, Rasmussen LH, Lip GY Tags: Thromb Haemost Source Type: research

Reasons for exclusion from intravenous thrombolysis in stroke patients admitted to the Stroke Unit
AbstractIntravenous (IV) thrombolysis is the treatment in ischemic stroke, but only the minority of patients receive this medication. The primary objective of this study was to explore the reasons associated with the decision not to offer IV thrombolysis to stroke patients admitted to the Stroke Unit (SU). We conducted a retrospective analysis based on data collected from 876 consecutive stroke patients admitted to the SU  <12  h of symptoms onset, treated or not with IV thrombolysis at the discretion of the treating neurologist. Of the 876 patients, 449 were thrombolysed and 427 non-thrombolysed. Stroke onset >4....
Source: Journal of Thrombosis and Thrombolysis - August 5, 2016 Category: Hematology Source Type: research

Filaggrin loss-of-function mutations as risk factors for ischemic stroke in the general population.
CONCLUSION: In this study of 97,174 individuals from the Danish general population, FLG loss-of-function mutations were associated with increased ischemic stroke risk; however, residual confounding is a possibility. This article is protected by copyright. All rights reserved. PMID: 28164424 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 5, 2017 Category: Hematology Authors: Varbo A, Nordestgaard BG, Benn M Tags: J Thromb Haemost Source Type: research

Dynamic Changes of CHA2DS2-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study.
CONCLUSION:  In AF patients, stroke risk as assessed by the CHA2DS2-VASc score is dynamic and changes over time. Rates of ischaemic stroke increased when patients accumulated risk factors, and were re-classified into higher CHA2DS2-VASc score categories. Stroke risk assessment is needed at every patient contact, as accumulation of risk factors with increasing CHA2DS2-VASc score translates to greater stroke risks over time. PMID: 29723875 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 3, 2018 Category: Hematology Authors: Yoon M, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Pak HN, Lee MH, Lip GYH, Joung B Tags: Thromb Haemost Source Type: research

Vascular Proteomics Reveals Critical Roles of ADAMTS18 in Stroke Associated with Imbalanced Level of Von Willebrand Factor Versus ADAMTS13
Conclusion and Significance-Results of this first vascular proteomic study of Adamts18 KO mice establish a substantial new resource for investigation of how ADAMTS gene affects cellular phenotypes of stroke. These new findings contribute to inform novel prevention strategies and direct therapeutic development for stroke.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Zhu, R., Pan, Y.-H., Lu, T., Dang, S., Liao, C.-C., Zhang, W. Tags: 301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: Poster III Source Type: research

Effect of prothrombotic genotypes on the risk of venous thromboembolism in patients with and without ischemic stroke.The Troms Ø Study.
CONCLUSIONS: Prothrombotic genotypes increased the risk of VTE in stroke patients, and the risk increased with increasing number of risk alleles. This article is protected by copyright. All rights reserved. PMID: 30773804 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 18, 2019 Category: Hematology Authors: Rinde LB, Morelli VM, Småbrekke B, Mathiesen EB, Løchen ML, Njølstad I, Wilsgaard T, Smith E, Rosendaal FR, Frazer KA, Braekkan SK, Hansen JB Tags: J Thromb Haemost Source Type: research